Miroestrol is a potent phytoestrogen compound with multifaceted biological effects. It induces a mammogenic effect and demonstrates neuroprotective properties, along with the ability to prevent bone loss in ovariectomized mice. Additionally, Miroestrol has been shown to reduce the risk of cancer [4].

Miroestrol, administered subcutaneously at doses ranging from 0.1 to 1 mg/kg daily for 60 days, effectively prevents bone loss in ovariectomized mice by increasing the ratio of osteoprotegerin to receptor activator of nuclear factor kappa B ligand (osteoformation/osteoresorption)[2]. Additionally, when given intraperitoneally at the same dosage daily for 8 weeks, it dose-dependently mitigates cognitive dysfunction induced by ovariectomy in mice[3]. Moreover, a daily subcutaneous administration of miroestrol at doses between 0.5 and 5 mg/kg for a period of 7 days has been shown to suppress hepatic CYP1A1 and CYP1A2 activity, as well as the expression of CYP1B1 mRNA and the protein expressions of CYP1A1/2 and CYP1B1 in mice treated with β-naphthoflavone[4].